IP Library Granted Patent US 10,578,626
Granted Patent B2
US 10,578,626 · App. 15/313,034 · Granted Mar 3, 2020

Kit for rapidly testing myocardial infarction and a preparation method and an application thereof

Inventors: Wenbo Hu (Beijing, CN); Jing Li (Jiangsu, CN)
Assignees: EACHY BIOPHARMACEUTICALS CO., LTD.; Wenbo Hu
G01N33/6893G01N33/533G01N33/54313G01N33/558G01N2333/47G01N2333/4704G01N2333/4712G01N2333/70567G01N2333/908G01N2800/324
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,578,626
App. No.
15/313,034
Granted
Mar 3, 2020
Kind
B2
Abstract

Disclosed are a kit for testing myocardial infarction rapidly and a preparation method and use thereof. The kit comprises a strip capable of detecting three markers, namely, human myeloperoxidase (MPO), heart-fatty acid binding protein (FABP3) and cardiac troponin I (cTnI) simultaneously. The strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad. Antibodies of the three markers are all marked on the conjugate pad. The chromatographic membrane has three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively. The kit has advantages such as convenient operation, rapid response, high sensitivity and high specificity, point of care test, and economical and practical etc.

Claims (18)

1. A kit for testing myocardial infarction rapidly, comprising a strip capable of detecting three markers, namely, human myeloperoxidase, heart-fatty acid binding protein and cardiac troponin I simultaneously;

wherein the strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad, antibodies of the three markers being all marked on the conjugate pad, and the chromatographic membrane having three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively;

wherein the antibodies of the three markers are anti-human myeloperoxidase mouse monoclonal antibody, anti-heart-fatty acid binding protein mouse monoclonal antibody and anti-cardiac troponin I mouse monoclonal antibody, respectively, paired antibodies of the three markers are anti-human myeloperoxidase monoclonal or polyclonal antibody, anti-heart-fatty acid binding protein monoclonal or polyclonal antibody, and anti-cardiac troponin I monoclonal or polyclonal antibody, respectively; and

wherein the sample pad, the conjugate pad, the chromatographic membrane and the absorbent pad are stickered on a base pad successively, the three test lines of the chromatographic membrane are parallel and are sequentially arranged along the length of the chromatographic membrane, the test line close to the conjugate pad coats paired antibody of human myeloperoxidase, the test line close to the absorbent pad coats paired antibody of cardiac troponin I, and the test line in the middle coats paired antibody of heart-fatty acid binding protein.

2. The kit for testing myocardial infarction rapidly according to claim 1 , wherein the conjugate pad is a colloidal gold pad and the kit is a colloidal gold immunoassay kit.

3. The kit for testing myocardial infarction rapidly according to claim 2 , wherein the kit further comprises a colourimetric card and/or a colloidal gold quantitative reader.

4. The kit for testing myocardial infarction rapidly according to claim 3 , wherein the kit comprises a colourimetric card, the colourimetric card comprises three lines from light to dark red which are printed on a white background which are standard lines of the three markers, respectively, the different shades of color of each red line represent different concentrations of each standard sample.

5. The kit for testing myocardial infarction rapidly according to claim 1 , wherein the conjugate pad is a fluorescence microparticles conjugate pad, and the kit is a fluorescence microparticles immunoassay kit.

6. The kit for testing myocardial infarction rapidly according to claim 5 , wherein the kit further comprises an immunofluorescence quantitative reader.

7. A preparation method of the kit for testing myocardial infarction rapidly according to claim 1 , comprising following steps:

(1) preparing the colloidal gold pad, which comprises preparing colloidal gold solution, taking three aliquot of the colloidal gold solution and adjusting pH to 7.5-8.5, respectively, adding the antibodies of the three markers into the three aliquot of the colloidal gold solution in the way that add 0.5-2 mg antibody into per 100 ml colloidal gold solution, respectively, stirring 1.5-3 h at room temperature, adding bovine serum albumin and polyethylene glycol to block the surface of the colloidal gold solution, centrifuging, discarding the supernatant, redissolving the precipitate in colloidal gold work-solution which is borate buffer in pH7.9-8.1 and contains 0.8 wt %-1.2 wt % bovine serum albumin, 8 wt %-12 wt % goat serum, 1.5 wt %-2.5 wt % sucrose and 0.1 wt %-0.5 wt % surfactant, then spreading on a glass fiber membrane or non-woven fabrics, drying for 2-5 h in a drying room which has temperature of 20-25° C. and humidity less than 30% to obtain the colloidal gold pad;

(2) preparing the chromatographic membrane, which comprises preparing 0.5-2 mg/ml solutions of the paired antibodies of the three makers with buffer in pH7-8, respectively, preparing 0.5-2 mg/ml solution of goat anti mouse IgG monoclonal or polyclonal antibody with buffer in pH7-8, drawing lines with the four solutions by a dispenser with a parameter of 1-1.5 ul/cm on an upper part, a middle part and a lower part of a nitrocellulose membrane, respectively, to obtain three test lines and one quality control line, drying for 2-5 h in a drying room which has temperature of 20-25° C. and humidity less than 30%;

(3) assembling the strip, which comprises adhering the sample pad, the conjugate pad, the chromatographic membrane, and a sample absorption pad successively to a plastic base pad in a drying room which has temperature of 20-25° C. and humidity less than 40%, cutting into the strip.

8. A preparation method of the kit for testing myocardial infarction rapidly according to claim 1 , comprising following steps:

(1) preparing the fluorescence microparticles conjugate pad, which comprises mixing the fluorescence microparticles with the antibodies of the three markers to obtain the antibody labeled fluorescence microparticles, then spreading the antibody labeled fluorescence microparticles on a glass fiber membrane or non-woven fabrics to obtain the fluorescence microparticles conjugate pad;

(2) preparing the chromatographic membrane, which comprises preparing 0.5-2 mg/ml solutions of the paired antibodies of the three makers with buffer in pH7-8, respectively, preparing 0.5-2 mg/ml solution of goat anti mouse IgG monoclonal or polyclonal antibody with buffer in pH7-8, drawing lines with the four solutions by a dispenser with a parameter of 1-1.5 ul/cm on an upper part, a middle part and a lower part of a nitrocellulose membrane, respectively, to obtain three test lines and one quality control line, drying for 2-5 h in a drying room which has temperature of 20-25° C. and humidity less than 30%;

(3) assembling the strip, which comprises adhering the sample pad, the conjugate pad, the chromatographic membrane, and a sample absorption pad successively to a plastic base pad in a drying room which has temperature of 20-25° C. and humidity less than 40%, cutting into the strip.

9. Use of the kit for testing myocardial infarction rapidly according to claim 1 for early warning and monitoring of myocardial infarction.

Assignments (2)
CHANGE OF NAME Recorded Nov 4, 2019
From: GOLDBIOMARKERS DIAGNOSTICS CO., LTD.
To: EACHY BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 050925/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2016
From: LI, JING
To: GOLDBIOMARKERS DIAGNOSTICS CO., LTD.; HU, WENBO
Reel/Frame 040661/0226 →
Priority Claims (2)
CN 2014 1 0217355 · May 22, 2014 · national
CN 2015 1 0012402 · Jan 9, 2015 · national
Continuity (1)
Related Publication 20170219608A1 · Aug 3, 2017